ADC, IntoCell sign MTA to conjugate antibody and perform toxicology experiments

IntoCell, a South Korean biotech developing novel antibody drug conjugate, or ADC, platform technologies, has signed a material transfer agreement, or MTA, with option to license with ADC Therapeutics. Under the agreement, IntoCell will provide proprietary drug-linkers developed using its Ortho-Hydroxy Protected Aryl Sulfate system and payload modification technology. ADC Therapeutics, a commercial-stage biotechnology company developing next-generation ADCs, will conjugate its antibody to IntoCell’s drug-linker and perform in vitro, in vivo, and toxicology experiments.